Radical solutions.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33824513.
- Also identified by DOI 10.1038/s41587-021-00908-5 and PMC identifier 8023346.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The US RADx program has spawned a phalanx of diagnostic products to market in just 12 months. Its long-term impact on point-of-care, at-home and population testing may be even more profound.
Medical subject headings
- COVID-19
- Direct-To-Consumer Screening and Testing
- Drug Development
- Point-of-Care Systems